Drugs / XL102
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04726332 | Feb 2021 → May 2024 | castration-resistant prostate carcinoma, hormone receptor-positive breast cancer, malignant epithelial tumor of ovary, triple-negative breast carcinoma | Exelixis | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XL102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04726332 ↗ |
| Action | Inhibit | “XL102, a highly specific, orally bioavailable covalent inhibitor of CDK7.” PMID 37507802 ↗ Jul 2023 |
| Route | Oral | “XL102 administered orally alone and in multiple combination regimens” NCT04726332 ↗ |
| Target | CDK7 | “XL102, a highly specific, orally bioavailable covalent inhibitor of CDK7.” PMID 37507802 ↗ Jul 2023 |